Trial Profile
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Intracranial embolism
- Focus Therapeutic Use
- Acronyms ODIn-AF
- 20 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2020 Status changed from suspended to active, no longer recruiting.
- 16 Aug 2019 Status changed from recruiting to suspended.